Company intelligence
Opal Ventures
Backing the next generation of healthcare infrastructure
Venture Capital and Private Equity Principals
4 employees
2 public signals
Verified activity
Signals from Opal Ventures
2 published signals
Legal & Regulatory
Opal Ventures noted that an FDA advisory committee voted to put four of the banned peptides on the market this month.
Reported by Owen Willis
Partnerships
Opal Ventures facilitated a partnership between Weave Bio and Takeda to power key drug development activities through their AI-native regulatory automation platform.
Reported by Owen Willis